OWKIN

Preprint on bioRxiv: We characterized OKN4395, a first-in-class triple antagonist targeting EP2, EP4, and DP1 receptors that addresses prostanoid-driven immunosuppression in solid tumors. 🔬 Triple mechanism addresses redundancy: PGE2-EP2/EP4 and PGD2-DP1 pathways use the same cAMP mechanism to suppress T and NK cells, so blocking one pathway alone can be bypassed by the other. OKN4395 performs equipotent blockade (IC50: 8.1 nM EP2, 26.6 nM EP4, 11.4 nM DP1). 📈 Preclinical validation: OKN4395 restored immune function in vitro and achieved 37% complete responses when combined with anti-PD1 in preclinical models. 🤖 K Pro helped accelerate this work by analyzing literature and omics data to generate testable hypotheses about the DP1 axis, which we validated in the lab. 💊 Phase 1 trial now underway as monotherapy and in combination with anti-PD1 (NCT06789172) - K Pro helped inform the clinical trial design. Read the preprint: https://lnkd.in/gMbatTcB Thanks to all the authors Maximilien Grandclaudon, Morgane Boulch, Anna Thaller, Jonathan Sabio Ortiz, Alexandre Grimaldi, PhD, Marie Goxe, Agnes Knopf, Marie Daugan, Eva Huehn, Carmela Gnerre, Sébastien Jeay, Monica Faronato, Haithem Dakhli, Silvia Lopez-Lastra, PhD, Alexandra Hardy, Sandrine Sanchez, PhD, Imke Mayer, Rose Hoste, Floriane Montanari, Vassili Soumelis, Joan Alberti, Lucia Pattarini, Caroline Hoffmann, Andrew Pierce

🎤 “now the questions are how do we find the targets that in combination will actually be transformational” Catch up on our podcast where Thomas Clozel and Jorge Reis-Filho discuss the future of Pharmaceutical companies in an AI world, how spatial biology can live up to its promise, and using AI to help us understand the best way to deliver medicines. 25 mins long. Watch here. https://lnkd.in/emrT5VH3

🎤 “the type of company that will win going forward is the one that brings domain knowledge, with technical expertise and the right infrastructure, in terms of compute, models, agents - and most importantly, data” Catch up on our podcast where Thomas Clozel and Jorge Reis-Filho discuss the future of Pharmaceutical companies in an AI world, how spatial biology can live up to its promise, and using AI to help us understand the best way to deliver medicines. 25 mins long. Watch here. https://lnkd.in/emrT5VH3

🎤 Thomas Clozel sits down with Astrazeneca’s Head of AI for Science Innovation Jorge Reis-Filho in our continuing Owkin podcast where we talk to leaders in AI, Biotech and Pharma about the changing world of AI in healthcare. Thomas and Jorge discuss the future of Pharmaceutical companies in an AI world, how spatial biology can live up to its promise, and using AI to help us understand the best way to deliver medicines. 25 mins long. Watch here. https://lnkd.in/emrT5VH3

Should we include this in our AI agent for biology K Pro? 🤖 We built a tool to solve a problem we kept running into: spending days trying to reproduce bioinformatic and computational biology methods from papers. Paper-to-Skills extract methodologies from scientific papers and turns them into executable skills for Claude Code. We're in beta testing right now and would love to hear what works (and what doesn't) for your use cases. 👉 Try it out and let us know what you think: https://lnkd.in/dpM7QcAY What methods are you currently spending the most time re-implementing? Drop a comment - it'll help us prioritize what to improve.

AI that connects research to care! Last night, on #WorldCancerDay, ARTE covered RlapsRisk BC, a next-generation risk profiling solution designed to assess the risk of relapse of early breast cancer patients with AI and routine histopathology slides. 📹 In the video, Owkin Dx Chief Diagnostics Officer, Meriem Sefta and Product Director, Victor Aubert, discuss: ⚙️ how the solution works 💥 the potential impact for patients where accurate risk assessment could help to drive more personalized care 🤝 Our close collaboration with Gustave Roussy on the development and validation of this product. Owkin is commited to delivering AI that connects research to care, with solutions like RlapsRisk BC demonstrating the power of AI in predicting patient outcomes, particularly when those tests leverage rich ground truth data found in pathology slides. Watch the ARTE feature here: https://lnkd.in/ex4iQF9x Learn more about RlapsRisk BC here: https://lnkd.in/gWGVDhU9 RlapsRisk BC is developed within the PortrAIt consortium.

A year ago, at the Paris AI Action Summit, 130 researchers gathered for a groundbreaking hackathon co-hosted by Owkin and Servier to tackle glioblastoma using AI and multimodal data. One year later, the momentum continues. Our top two teams have made substantial scientific advances: 🔬 Team SpaceAix has identified prognostic signatures and the multicellular communication networks that drive glioblastoma progression 🧬 Team Glioblasters has mapped spatial cellular niches within the tumor microenvironment that correlate with patient survival These discoveries open promising avenues to connect research to care by improved patient stratification and targeted therapeutic approaches. Both teams are now advancing their work toward publication. This progress was enabled by a unique ecosystem: Owkin's MOSAIC research dataset, spatial omics from 10x Genomics, spatial proteomics from the Parker Institute for Cancer Immunotherapy's BRUCE cohort, foundation models from Bioptimus, and compute infrastructure from Amazon Web Services (AWS). Read our previous blog and stay tuned for the full results: https://lnkd.in/eZAkCWYs This success demonstrates the power of AI to unlock hidden biological insights in complex diseases, and it's just the beginning of what's possible when we bring together the right data, technology, and talent.

Next week, our CEO Thomas Clozel will be speaking at the Handelsblatt Annual Conference Thomas will discuss ‘AI Biotech in Action: How Multimodal Data Is Shaping the Next Generation of Drug Discovery and Development’ 📅 February 9 | 🕐 11:10 - 11:30 am CET | Berlin, Germany Don’t miss Thomas’ talk to learn how we’re building AI that connects research to care: https://lnkd.in/d5XvD9zt

🚀 Turn scientific methods into AI skills - instantly Ever tried to reproduce a bioinformatics or computational biology method from a paper… and took days to set it up? With Owkin’s Paper-to-Skills app, you can extract specific methodologies and techniques from scientific papers and generate skills you can use in Claude Code - in minutes. 🧑🏼💻 How it works • Upload a paper • Extract the methodologies • Convert them into executable skills • Run skills in Claude Code No more re-implementing long pipelines. No more guesswork. 👉 Create your first skill for free now: https://lnkd.in/dpM7QcAY

📢 Our Chief Transformation Officer Andrea Tassistro, will be speaking at La santé: vers une possible gouvernance européenne, co-hosted by Pergamon and APM International Paris. Andrea will participate in the panel "L’IA au service de la santé des Européens: opportunité et risques" alongside David Gruson, Director, Home Health Care Program, La Poste Santé & Autonomie and Aymeric Perchant, National Coordinator of the Digital Health Acceleration Strategy, Health Ministry. 📅 February 17 | 🕐 11:30 am - 12:00 pm CET at la Maison de l’Europe, 77 av. de Versaille, 75016 Paris Find out more about how Owkin is building European biological artificial superintelligence by unifying biomedical data across the continent, under European rules. Register now: https://lnkd.in/eMA-fv2B